Biomarkers /

MUC16

Back to Biomarkers List
Associated Genetic Biomarkers
Associated Diseases

Overview

Location [1]
19p13.2
Protein [2]
Mucin-16
Synonyms [1]
CA125

MUC16 is altered in 0.97% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma, breast neoplasm, and mucinous breast carcinoma having the greatest prevalence of alterations [3].

MUC16 GENIE Cases - Top Diseases

The most common alterations in MUC16 are MUC16 Amplification (4.50%), MUC16 S2952L (0.12%), MUC16 V8260M (0.12%), MUC16 A10976P (0.08%), and MUC16 E8069G (0.08%) [3].

MUC16 GENIE Cases - Top Alterations

Clinical Trials

View Clinical Trials for MUC16

Significance of MUC16 in Diseases

Fallopian Tube Carcinoma +

Primary Peritoneal Carcinoma +

Ovarian Carcinoma +

Malignant Ovarian Epithelial Tumor +

Ovarian Epithelial Tumor +

Pancreatic Ductal Adenocarcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.